Development, Screening, and Validation of Camelid-Derived Nanobodies for Neuroscience Research.
Development, Screening, and Validation of Camelid-Derived Nanobodies for Neuroscience Research.
复制标题
DOI:
10.1002/cpns.107
复制
发表时间:
2020-12
影响因子:
--
通讯作者:
Trimmer JS
中科院分区:
文献类型:
--
作者:
Gavira-O'Neill CE;Dong JX;Trimmer JS
Nanobodies (nAbs) are recombinant antigen binding variable domain fragments obtained from the heavy chain only immunoglobulins. Among mammals these are unique to camelids (camels, llamas, alpacas, etc.). Nanobodies are of great use in biomedical research due to their efficient folding and stability under a variety of conditions, as well as their small size. The latter characteristic is particularly important for nAbs used as immunolabeling reagents since this can improve penetration of cell and tissue samples compared to conventional antibodies, as well as reduce the gap distance between signal and target thereby improving imaging resolution. In addition, their recombinant nature allows for unambiguous definition and permanent archiving in the form of DNA sequence, enhanced distribution in the form of sequences or plasmids, and easy and inexpensive production using well-established bacterial expression systems, such as the IPTG induction method described here. This unit will review the basic workflow and process for developing, screening and validating novel nAbs against neuronal target proteins. The protocols described make use of the most common nAb development method, wherein an immune repertoire from an immunized llama is screened via phage display technology. Selected nAbs can then be taken through validation assays for use as immunolabels or as intrabodies in neurons.